Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands

• المؤلفون الرئيسيون: Diane E.T. Bastiaans, Silvia Forcat, Hermione Lyall, Tim R. Cressey, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Antoni Noguera-Julian, Christoph Konigs, Jamie R.J. Inshaw, Suwalai Chalermpantmetagul, Yacine Saidi, Alexandra Compagnucci, Lynda M. Harper, Carlo Giaquinto, Angela P.H. Colbers, David M. Burger
• التنسيق: دورية
• منشور في: 2018
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84890378736&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/45156

© 2013 by Lippincott Williams & Wilkins. Background: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight...